- Home
- HTH vs ZYME Comparison
HTH vs ZYME Comparison
Compare HTH & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTH | ZYME |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2003 | 2022 |
Fundamental Metrics
Financial Performance| Metric | HTH | ZYME |
|---|---|---|
| Price | $34.75 | $22.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $37.50 | ★ $38.90 |
| AVG Volume (30 Days) | 314.9K | ★ 630.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.29% | N/A |
| EPS Growth | ★ 51.72 | 33.33 |
| EPS | ★ 2.64 | N/A |
| Revenue | ★ $152,188,000.00 | $105,965,000.00 |
| Revenue This Year | N/A | $162.82 |
| Revenue Next Year | $3.07 | N/A |
| P/E Ratio | $13.21 | ★ N/A |
| Revenue Growth | 15.52 | ★ 38.87 |
| 52 Week Low | $27.35 | $9.03 |
| 52 Week High | $40.41 | $28.49 |
Technical Indicators
Market Signals| Indicator | HTH | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 31.12 | 43.81 |
| Support Level | $34.27 | $22.23 |
| Resistance Level | $35.69 | $23.66 |
| Average True Range (ATR) | 0.98 | 1.42 |
| MACD | -0.45 | -0.05 |
| Stochastic Oscillator | 1.68 | 9.06 |
Price Performance
Historical ComparisonAbout HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. The company has three segments: The banking segment includes the operations of the Bank; The broker-dealer segment includes the operations of Securities Holdings,; and the mortgage origination segment is composed of PrimeLending. Majority of revenue is from Broker-dealer Segment.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.